-PDF Download- Hepatitis C Virus And Liver Transplantation EBOOK

Liver Transplantation

Author: James Neuberger

Publisher: John Wiley & Sons

Published: 2021-02-25

Total Pages: 592

ISBN-13: 1119633990

Explore this practical and step-by-step guide to managing liver transplant patients from leading international clinicians in Hepatology The newly revised Second Edition of Liver Transplantation: Clinical Assessment and Management delivers expert clinical guidance on best practices in managing the care of liver transplant patients. Authors are all experts in their field and cover a world-wide perspective. Organized in an accessible, stepwise fashion and packed with text features such as key points, the book covers all critical areas of each stage of the liver transplant journey, from assessment, to management on the list, to long term care. Readers will learn when to refer a patient for liver transplantation, how to assess a potential liver transplant recipient, learn the principles of the procedure and the long term management of the transplant recipient. Liver Transplantation provides the entire hepatology and surgical team the information required for a sound understanding of the entire procedure, from pre- to post-operative care and management. Clinically oriented and management-focused, the book is far more accessible than the liver transplant sections in traditional hepatology textbooks. Readers will also enjoy: A thorough discussion of when to refer a patient for liver transplantation, including general considerations and the use and abuse of prognostic models An exploration of the selection, assessment, and management of patients on the transplant list, including how to manage a patient with chronic liver disease while on the waiting list A treatment of liver transplantation for acute liver failure (ALF), including assessment and management of ALF patients on the transplant waiting list A discussion of care of the liver transplant recipient after the procedure in the short and long term Perfect for gastroenterologists, hepatologists, and surgeons and other health care professionals managing patients with liver disease who are awaiting, undergoing and following liver transplantation, Liver Transplantation: Clinical Assessment and Management will also earn a place in the libraries of medical students, residents, internal medicine physicians, and GI/Hepatology trainees and all health care professionals providing clinical care to people with liver disease, before, during and after transplantation.

Hepatitis C Virus and Liver Transplantation

Author: Marina Berenguer

Publisher: Springer Science & Business Media

Published: 2013-09-11

Total Pages: 128

ISBN-13: 1461484383

DOWNLOAD EBOOK →

Hepatitis C Virus and Liver Transplantation is designed to provide a comprehensive and state-of-the-art overview of the major issues specific to the field of liver transplantation and hepatitis C virus infection. The sections of the book have been structured to review the overall scope of issues of recurrent hepatitis C in different complex settings, including retransplantation, HIV-coinfected patients or in the setting of suboptimal graft donors. This book provides up-to-date information on the application of new therapies to the field of liver transplantation. It provides the most recent data on their efficacy, the management of side effects, as well as the potential interactions and specific problems associated with their use in the transplant setting. Finally, an appraisal of the risks and benefits of using organs from anti-HCV positive donors is presented. This book provides concise and actual materials for several important topics that are simply not adequately covered by current available literature. Hepatitis C Virus and Liver Transplantation will provide a unique and valuable resource in the field of liver transplantation and will be of great value to Hepatologists, Transplant and Abdominal Surgeons, Oncologists, as well as Fellows and Residents training in these fields.

Chronic Hepatitis C Virus

Author: Mitchell L. Shiffman

Publisher: Springer Science & Business Media

Published: 2011-11-17

Total Pages: 333

ISBN-13: 1461411920

DOWNLOAD EBOOK →

Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.

Hepatitis C in Renal Disease, Hemodialysis and Transplantation

Author: J.M. Morales

Publisher: Karger Medical and Scientific Publishers

Published: 2012-01-23

Total Pages: 143

ISBN-13: 3805598211

DOWNLOAD EBOOK →

Hepatitis C virus (HCV) infection is a major health problem worldwide, with currently over 150 million HCV-infected people on the five continents. Although there have been important advances in the diagnosis, prevention and therapy, the infection remains an important health problem in most countries.HCV infection is considered a systemic disease: Not only does it affect the liver, it can induce autoimmune, dermatological and renal disease. Moreover, soon after the discovery of HCV as the major cause of non-A non-B hepatitis, HCV infection was recognized as an important cause and consequence of chronic kidney disease. The publication at hand is an update on the most important topics concerning HCV infection, renal disease and problems with dialysis in the general population as well as in renal transplant patients. Also included is a chapter on the emerging problem of renal complications associated with HCV virus in patients with HIV infection.Containing contributions from a panel of internationally acclaimed experts, this publication is a timely update on HCV infection and the kidney.

Liver Transplantation, An Issue of Clinics in Liver Disease, E-Book

Author: David Goldberg

Publisher: Elsevier Health Sciences

Published: 2020-11-24

Total Pages: 273

ISBN-13: 032379193X

DOWNLOAD EBOOK →

With collaboration from Consulting Editor, Dr. Norman Gitlin Dr. Goldberg has assembled a state-of-the-art issue devoted to management of liver transplant patients. Expert authors have contributed current clinical reviews that covers the breadth of the pre- and post-surgical journey. Articles are specifically devoted to the following topics: Obesity management of liver transplant waitlist candidates and recipients; Expanding the limits of liver transplantation for hepatocellular carcinoma: Is there a limit; Frailty and sarcopenia in patients pre- and post-liver transplant; Achieving tolerance in liver transplantation: Where are we now and what does the future hold; Expanding role of donation after cardiac death donors; Optimizing selection of patients for simultaneous liver-kidney transplant; Keeping the patient with end-stage liver disease alive while awaiting transplant: Management of complications of portal hypertension; Expanding donor selection and recipient indications for living donor liver transplantation; The changing liver transplant recipient: From hepatitis C to NASH and alcohol; Cardiovascular risk stratification in liver transplant candidates; The role of machine perfusion in liver transplantation: Warm, Cold, or does it not matter; Paradigm shift in utilization of livers from hepatitis C-viremic donors into HCV-negative patients; Transplantation of elderly patients: Is there an upper age cutoff; Transplantation for acute alcoholic hepatitis: Controversies and early successes. Hepatologists will come away with the information they need to improve outcomes in liver transplant patients.

Liver Transplantation in Patients with Hepatitis C

Author: Tajana Filipec Kanižaj

Publisher:

Published: 2017

Total Pages:

ISBN-13:

DOWNLOAD EBOOK →

As a leading indication for liver transplantation in Western countries, hepatitis C virus (HCV) poses a significant burden both before and after transplantation. Post-transplant disease recurrence occurs in nearly all patients with detectable pre-transplant viremia, therefore compromising the lifesaving significance of transplantation. Many factors involving the donor, recipient and virus have been evaluated throughout the literature, although few have been fully elucidated and implemented in actual clinical practice. Antiviral therapy has been recognized as a cornerstone of HCV infection control; however, experience and success are limited following transplantation in a challenging cohort of patients with liver cirrhosis. Current therapeutic protocols surpass those that were used previously, both in regards to sustained viral response (SVR) and the side-effect profile.

Eliminating the Public Health Problem of Hepatitis B and C in the United States

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2016-06-01

Total Pages: 187

ISBN-13: 0309438020

DOWNLOAD EBOOK →

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Chronic Hepatitis C Virus

Author: Mitchell L. Shiffman

Publisher: Springer

Published: 2012-02-10

Total Pages: 332

ISBN-13: 9781461411932

DOWNLOAD EBOOK →

Liver Transplantation: Update of Concepts and Practice, An Issue of Clinics in Liver Disease

Author: Kalyan Ram Bhamidimarri

Publisher: Elsevier Health Sciences

Published: 2014-08-28

Total Pages: 265

ISBN-13: 032332035X

DOWNLOAD EBOOK →

A number of areas within liver transplant continue to evolve as the field matures. The advent of increasingly effective therapy for HCV will dramatically reduce the burden of recurrent disease within the next few years. HCC has become a well established indication for transplant with an increasing emphasis on adjuvant therapies to reduce the risk of tumor recurrence and potentially expand the acceptable limits of tumor burden amenable to liver transplant. Renal dysfunction is a frequent complication of decompensated liver disease and an important predictor of diminished post-transplant survival. Newer approached to therapy including terlipressin will reduce the impact of renal dysfunction in liver transplant candidates and potentially reduce the need for combined liver/kidney transplant. Increasing attention is being paid to role of comorbidities such as diabetes and hypertension on long-term recipient outcomes. Retransplantation remains a challenge with a variety of models available to predict outcomes. Cardiac disease pretransplant is an area of active investigation with newer entities such as cirrhotic cardiomyopathy a growing concern. These are some of many evolving issues in liver transplant which will be addressed to update our readers and which in turn will enhance the care of patients with liver disease.

Management of Hepaitits C Virus Genotype 4 in the Liver Transplant Setting

Author: Waleed K. Al-Hamoudi

Publisher:

Published: 2017

Total Pages:

ISBN-13:

DOWNLOAD EBOOK →

End-stage liver disease secondary to hepatitis C virus (HCV) infection is the major indication for orthotopic liver transplantation (OLT) worldwide. It also has a negative impact on patient and graft survival leading to an inferior transplant outcome when compared to other liver transplant indications. The percentage of HCV patients infected with genotype 4 (G4) among recipients of OLT varies depending on geographic location. In the Middle East G4 infection is the most common genotype among transplant recipients. Direct antiviral agents (DAAs) have revolutionized the management of HCV infection in the pre- and post-transplant setting. Recent clinical trials have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon (PEG-IFN)-based therapy. However, most of these studies were performed in HCV-G1-infected patients. Due to the low prevalence of HCV-G4 in Europe and the USA, this genotype has not been adequately studied in prospective trials evaluating treatment outcomes. The aim of this chapter is to summarize the natural history and treatment outcome of HCV-G4 in the liver transplant setting, with particular attention to new HCV therapies.